- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
GSK and Novo Nordisk Lead on Access Index
Last week, the Access to Medicine Foundation released its 2014 Index rating the performance of companies in broadening access to medicines in low and middle-income countries.
Last week, the Access to Medicine Foundation released its 2014 Index rating the performance of companies in broadening access to medicines in low and middle-income countries.
For the fourth time, GSK leads the index with Novo Nordisk taking second. J&J. Novartis, Gilead and Merck KGaA rank three to six with nearly even scores.
Download the report here.
Novo Nordisk leapt from sixth to second with improvements in five of the seven areas the index analyzes.
Also making impressive gains in index rankings were Novartis, Merck KGaA and Eisai. Some companies that took tumbles in the rankings were Pfizer, Eli Lilly and Takeda.
Astellas, Daiichi Sankyo and Takeda are at the bottom of the index ranking 18th, 19th and 20th.
The index is built on business activity in seven areas with four strategic pillars considered in each.
The foundation has refined what it measures and how it assesses the evidence resulting in “a clearer picture of industry strengths, weaknesses, progress and struggles – and a crystallised understanding of what it takes to be a leader in access to medicine,” according to Wim Leereveld, Index CEO and Founder.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
